Description: Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, we are building a synthetic biology platform that may enable us to program next-generation cell and gene therapies with what we refer to as Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We aim to design Gene Circuits to improve the intelligence of cell and gene therapies in order to enhance their therapeutic effectiveness, precision and durability against a broad range of diseases that conventional medicines do not readily address. Our synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with these Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. Our lead programs include SENTI-202 and SENTI-301. SENTI-202 is a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow. SENTI-301 is a Multi-Armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). We anticipate filing Investigational New Drug (IND) applications in 2023 for both candidates. Over the past several months, Senti Bio scientists have presented preclinical proof-of-concept data across various programs including at the annual meetings of the American Society of Gene and Cell Therapy (ASGCT), the American Association for Cancer Research (AACR), and the American Society of Hematology (ASH). We have also demonstrated the breadth of our Gene Circuits in other modalities and diseases outside of oncology and have executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
Home Page: www.sentibio.com
SNTI Technical Analysis
2 Corporate Drive
South San Francisco,
CA
94080
United States
Phone:
(650) 382-3281
Officers
| Name | Title |
|---|---|
| Dr. Timothy K. Lu M.D., Ph.D. | Co-founder, CEO, Pres & Director |
| Dr. Philip Lee Ph.D. | Co-Founder & CTO |
| Ms. Susan D. Berland | Sr. Financial Exec. & Independent Director |
| Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director |
| Dr. Wilson Wong Ph.D. | Scientific Co-Founder & Member of Scientific Advisory Board |
| Dr. Deborah A. Knobelman Ph.D. | CFO & Treasurer |
| Dr. Kanya Rajangam M.D., Ph.D. | Chief Medical & Devel. Officer |
| Susan Kahlert | Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4344 |
| Price-to-Sales TTM: | 13.2794 |
| IPO Date: | 2022-06-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |